SCHEMBL56557

SCHEMBL56557

NCC(Cc1ccccc1)(Cc1ccccc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
KIF11 P52732 6/20 0.48
TAAR1 Q96RJ0 3/20 0.46
SLC6A2 P23975 1/20 0.46
CYP3A4 P08684 2/20 0.46
RECQL P46063 1/20 0.46
MAPK1 P28482 1/20 0.45
LOXL2 Q9Y4K0 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
HIF1A Q16665 1/20 0.42
CYP2A6 P11509 1/20 0.41
HTR2A P28223 1/20 0.41
CYP2D6 P10635 1/20 0.39
PRMT1 Q99873 1/20 0.39
KCNA5 P22460 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9063882 0.85 CYP1A2 (0.58) CYP1A2CYP2C9CYP2C19KIF11TAAR1
SCHEMBL22609038 0.83 TAAR1 (0.56) KIF11TAAR1LOXL2SMN1; SMN2CYP2A6
SCHEMBL16636143 0.77 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19KIF11TAAR1
SCHEMBL7095560 0.77 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19KIF11TAAR1
Bromide SCHEMBL11785393 0.77 TAAR1 (0.46) CYP1A2CYP2C9CYP2C19KIF11TAAR1
SCHEMBL9584692 0.76 TAAR1 (0.50) CYP1A2CYP2C9CYP2C19KIF11TAAR1
SCHEMBL11843983 0.76 CYP1A2 (0.48) CYP1A2CYP2C9CYP2C19KIF11TAAR1
SCHEMBL6282930 0.74 TAAR1 (0.54) CYP1A2KIF11TAAR1CYP3A4CYP2D6
SCHEMBL8157569 0.74 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19KIF11TAAR1
Hydrochloric Acid SCHEMBL7677659 0.74 TAAR1 (0.48) CYP1A2CYP2C9CYP2C19KIF11TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004286-A1 BROAD TEMPERATURE PERFORMANCE CHEMILUMINESCENT SYSTEMS AND METHODS Cyalume Technologies, Inc (US) 2016-04-13 EP disclosed
WO-2014194332-A1 BROAD TEMPERATURE PERFORMANCE CHEMILUMINESCENT SYSTEMS AND METHODS Cyalume Technologies (US) 2014-12-04 WO disclosed
US-8426596-B2 Process of producing bleach boosters BASF AKTIENGESELLSCHAFT (DE) 2013-04-23 US disclosed
US-8426596-B2 Process of producing bleach boosters BASF AKTIENGESELLSCHAFT (DE) 2013-04-23 US disclosed
US-8129531-B2 Using an isoquinoline compound; alkylation of benzonitrile; reduction ofnitrile to an amine; cyclization BASF AKTIENGESELLSCHAFT (DE) 2012-03-06 US disclosed
US-8129531-B2 Using an isoquinoline compound; alkylation of benzonitrile; reduction ofnitrile to an amine; cyclization BASF AKTIENGESELLSCHAFT (DE) 2012-03-06 US disclosed
US-20110319622-A1 PROCESS OF PRODUCING BLEACH BOOSTERS BASF SE (DE) 2011-12-29 US disclosed
US-20110319622-A1 PROCESS OF PRODUCING BLEACH BOOSTERS BASF SE (DE) 2011-12-29 US disclosed
EP-1891192-B1 ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY PROCTER & GAMBLE (US) 2009-12-16 EP disclosed
US-20090149366-A1 ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY MIRACLE GREGORY SCOT 2009-06-11 US disclosed
US-20090149366-A1 ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY MIRACLE GREGORY SCOT 2009-06-11 US disclosed
US-7504371-B2 Organic catalyst with enhanced enzyme compatibility THE PROCTER & GAMBLE COMPANY (US) 2009-03-17 US disclosed
US-7504371-B2 Organic catalyst with enhanced enzyme compatibility THE PROCTER & GAMBLE COMPANY (US) 2009-03-17 US disclosed
US-20080214819-A1 Process of Producing Bleach Boosters BASF AKTIENGESELLSCHAFT (DE) 2008-09-04 US disclosed
US-20080214819-A1 Process of Producing Bleach Boosters BASF AKTIENGESELLSCHAFT (DE) 2008-09-04 US disclosed
US-20070197421-A1 Organic catalyst with enhanced enzyme compatibility PROCTER & GAMBLE COMPANY, THE 2007-08-23 US disclosed
US-20070197421-A1 Organic catalyst with enhanced enzyme compatibility PROCTER & GAMBLE COMPANY, THE 2007-08-23 US disclosed
WO-2007001261-A1 ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY THE PROCTER & GAMBLE COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214819-A1 Process of Producing Bleach Boosters SQLE, BCHE, CAT CYP1A2 48/4885CYP2C9 106/4885CYP2C19 189/4885
US-20110319622-A1 PROCESS OF PRODUCING BLEACH BOOSTERS SQLE, BCHE, CAT CYP1A2 48/4885CYP2C9 106/4885CYP2C19 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.